Key to treating Alzheimer's might be addressing the innate immune system due to chronic inflammation
R.J. Tesi MD is President and CEO of Inmune Bio (NASDAQ: INMB)
Dr. R.J. Tesi shines light on the complexity of the immune system by pointing out that while much work has been done on the adaptive immune system, the key to treating Alzheimer's might be to address the dysregulated innate immune system due to chronic inflammation.
R.J. talks about developing XPro1595 a second generation selective TNF inhibitor which is designed to reduce inflammatory activity in the brain.
INmune is also validating novel neuroimaging techniques and biomarkers to help predict which patients may respond to treating neuroinflammation as an underlying cause of their Alzheimer's.